Search Blog
July 2017


SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AngioDynamics, Inc. – ANGO


By Pomerantz LLP

NEW YORK, NY / ACCESSWIRE / July 21, 2017 / Pomerantz LLP is investigating claims on behalf of investors of AngioDynamics, Inc. (“AngioDynamics” or the “Company”) (NASDAQ: ANGO). Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 9980.

The investigation concerns whether AngioDynamics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On July 17, 2017, post-market, AngioDynamics announced that its auditor has determined that a material weakness existed in the Company’s internal control over financial reporting as of May 31, 2016 because AngioDynamics did not design and maintain effective internal controls over the accounting for the annual goodwill impairment test. Specifically, the Company lacked effective controls to review in sufficient detail the cash flow projections and significant valuation model assumptions used in the goodwill impairment test as of December 31, 2015.

On this news, AngioDynamics’ share price has fell as much as $0.91, or 5.61%, during intraday trading on July 18, 2017

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

SOURCE: Pomerantz LLP

ReleaseID: 469257